Erlotinib Resistance with EGFR L858R/Y891D Double Mutation in a Patient with Non-Small Cell Lung Cancer

J Thorac Oncol. 2019 Apr;14(4):e65-e68. doi: 10.1016/j.jtho.2018.12.031.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Drug Resistance, Neoplasm / genetics*
  • Erlotinib Hydrochloride / pharmacology
  • Erlotinib Hydrochloride / therapeutic use*
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Mutation

Substances

  • Antineoplastic Agents
  • Erlotinib Hydrochloride